Skip to main content
SpringerLink
Log in

Brofaromine — a review of its pharmacological properties and therapeutic use

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances — brofaromine — will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

A :

adrenaline

AUC :

area under curve

BECK :

Beck Depression Inventory

Bf-S :

Adjective Mood Scale (von Zerssen)

C max :

peak concentration

CGI :

Clinical Global Impression

DA :

dopamine

DB :

double-blind

DSM :

Diagnostic and Statistical Manual of Mental Disorders

ED :

effective dose

ECG :

electrocardiography

EEG :

electroencephalography

EM :

extensive metabolizers of debrisoqine

F> abs :

absolute bioavailability

GFR :

glomerulus filtration rate

HAMD :

Hamilton Depression Scale

5-HT :

serotonin

m :

months

MAO :

monoamine oxidase

MAOI :

monoamine oxidase inhibitor

NA :

noradrenaline

n.a. :

not applicable

MHPG :

3-methoxy-4-hydroxy-phenylglycol

PD :

presser dose

PEA :

2-phenyl-ethyl-amine

PM :

poor metabolizers of debrisoquine

REM :

rapid eye movement

1/2 :

half-life time

T max :

time to peak concentration

VAS :

visual analogue scale

w :

weeks

ZUNG :

Zung Self-Rating Depression Scale

References

  • Anderson MC, Waldmeier PC, Tipton KF (1991) The inhibition of monoamine oxidase by brofaromine. Biochem Pharmacol 41: 1871–1877

    Google Scholar 

  • Antonin KH, Jedrychowski M, Bieck PR (1990) Brofaromine. Pharmacodynamic and pharmacokinetic investigations in healthy subjects with a new reversible, selective MAO-A inhibitor. Mün Med Wochenschr 132 [Suppl 1]: 1, 13–17

    Google Scholar 

  • Antonin KH, Kucher K, Fuchs L, Bieck PR, Schmidt E (1992) Investigation of dose proportionality and absolute bioavailability of brofaromine in healthy volunteers. Clin Neuropharmacol 15 [Suppl 1]: Pt B, 430B (Abstract)

    Google Scholar 

  • Antonin KH, Fischer P, Nilsson E, Bieck PR (1994) Administration of L-DOPA and benserazide with the selective MAO-A inhibitor brofaromine in healthy volunteers: effect on blood pressure and DOPA metabolism. CINP, 120S

  • Antonin KH, Bieck PR (1994) Coadministration of brofaromine does not enhance insulin secretion and the hypoglycemic effect caused by glibenclamide. CINP, 120S

  • Baker GB, Courts RT, Young JM, Hampston DR, McIntosh GIJ, et al (1985) Chronic administration of monoamine oxidase inhibitors: basic and clinical investigations. In: Boulton AA, et al (eds) Neuropharmacology of the trace amines. Humana Press, Clifton NJ, pp 317–328

    Google Scholar 

  • Bianchi M, Mantegazza P, Panerai AE (1992) Effects of two different reversible monoamine oxidase-A inhibitors on nociceptive thresholds in the rat. Eur J Pharmacol 219: 113–116

    Google Scholar 

  • Bieck PR, Nilsson E, Schick C, Waldmeier PC, Lauber J (1984a) Urinary excretion of tryptamine in comparison to normetanephrine and beta-phenylethylamine in human volunteers after subchronic treatment with different monoamine oxidase inhibitors. In: Boulton AA, Baker GB, Dewhurst WG, Sandler M (eds) Neurobiology of the trace amines. Humana Press, Clifton NJ, pp 525–539

    Google Scholar 

  • Bieck PR, Antonin KH, Cremer G, Gleiter C (1984b) Tyramine pressor effects of CGP 11 305A in comparison to tranylcypromine after prolonged treatment of human volunteers. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 505–513

    Google Scholar 

  • Bieck PR, Kemmler H, Antonin KH, Tipton K (1988) Evidence of “local” gastrointestinal effects of MAO inhibition on metabolism and transport of tyramine in human subjects. Pharmacol Res Commun 20 [Suppl]: 129–130 (Abstract)

    Google Scholar 

  • Bieck PR, Antonin KH (1988) Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8: 237–245

    Google Scholar 

  • Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs. irreversible inhibitors. J Neural Transm 28 [Suppl]: 21–31

    Google Scholar 

  • Bieck PR, Firkusny L, Schick C, Antonin KH, Nilsson E, Schulz R, Schwenk M, Wollmann H (1989) Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45: 260–269

    Google Scholar 

  • Bieck PR, Antonin KH, Schulz R (1993) Clinical pharmacology of MAO-inhibitors. In: Yasuha H, Parvez SH, Oguchi K, Sandler M, Nagatsu S (eds) Monoamine oxidase: basid and clinical aspects. VSP, Utrecht, pp 177–196

    Google Scholar 

  • British Medical Research Council (1965) Clinical trial of the treatment of depressive disorders. Br Med J 1: 881–886

    Google Scholar 

  • Celada P, Pérez J, Alvarez E, Artigas F (1992) Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J Clin Psychopharmacol 12: 309–315

    Google Scholar 

  • Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradvwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Belanger ML, Snaith J, Beauclair L, Pohlmann H, D'Souza J (1994) A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 32: 105–114

    Google Scholar 

  • Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, pp 137–154

    Google Scholar 

  • Davidson J, Pelton S, Miller RD, Lipper S (1986) Endogenous depression and the response to isocarboxazid. In: Bunney WE, Costa E, Potkin SG (eds) Proceedings of the 15th Collegium Internationale Neuropsychopharmacologium, Vienna 1986. Raven Press, New York, pp 563–565

    Google Scholar 

  • Degen PH, Dieterle W, Schneider W, Czendlik C (1989) Pharmacokinetic interaction of H2-receptor antagonists on brofaromine-HCl. In: Stefanis CN, Soldates CR, Rabavilas AD (eds) Psychiatry today. 7th World Congress of Psychiatry, Athens. Excerpta Medica (Intern Congress Series 899, Abstract 405)

  • Degen PH, Cardot M, Czendlik C, Dieterle W (1993) Influence of food on the disposition of the monoamine oxidase A inhibitor brofaromine in healthy volunteers. Biopharm Drug Dispos 14: 209–215

    Google Scholar 

  • Delcker A, Gaertner HJ (1991) Tolerability and antidepressive effect of brofaromine, a short acting reversible MAO-inhibitor — an open study. Eur Neuropsychopharmacol 1: 177–180

    Google Scholar 

  • Delini-Stula A, Humm C (1986) Effects of imipramine and brofaromine, a selective and reversible MAO-A inhibitor, on novelty-oriented behavior in rats. Pharmacopsychiatry 19: 245–246

    Google Scholar 

  • Delini-Stula A, Radeke E, Waldmeier PC (1988) Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York Tokyo, pp 147–158

    Google Scholar 

  • Den Boer JM, van Vliet IM, Westenberg HGM (1992) A double-blind comparative study of fluvoxamine and brofaromine in panic disorder. Clin Neuropharmacol 15 [Suppl 1, Pt B]: 91B

    Google Scholar 

  • Fahlén T, Humble M, Koczak C, Nilsson HL (1992) Social phobia and its treatment with brofaromine. Efficacy regarding social phobia symptoms and personality traits. Psychopharmacology 107: B134

    Google Scholar 

  • Feifel N, Kucher K, Fuchs L, Jedrychowski M, Schmidt E, Antonin KH, Bieck PR, Gleiter CH (1993) Role of cytochrome P4502D6 in the metabolism of brofaromine, a new selective MAO-A inhibitor. Eur J Clin Pharmacol 45: 265–269

    Google Scholar 

  • Finberg JP, Youdim MBH (1988) Potentiation of tyramine presser responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm 71 [Suppl 26]: 11–16

    Google Scholar 

  • Fritze J, Becker T, Ziegler V, Laux G, Bieck P, Sofie E, Riederer P (1990) Brofaromine (CGP 11 305 A): estimation of plasma concentration by a biological technique as compared to liquid chromatography. J Neural Transm 23 [Suppl]: 197–201

    Google Scholar 

  • Garcia-Borreguerro D, Bronisch T (1992) Improvement of social phobic symptoms after treatment with brofaromine, a reversible and selective inhibitor of MAO-A. Eur Psychiat 7: 93–94

    Google Scholar 

  • Garcia-Borreguerro D, Lauer CJ, Özdaglar A, Wiedmann K, Holsboer F, Krieg J (1992) Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry 25: 261–264

    Google Scholar 

  • Gleiter CH, Mühlbauer B, Gradin-Frimmer G, Antonin KH, Bieck PR (1992a) Administration of sympathomimetic drugs with the selective MAO-A inhibitor brofaromine. Effect on blood pressure. Drug Invest 4: 149–154

    Google Scholar 

  • Gleiter CH, Nilsson E, Mühlbauer B, Antonin KH, Bieck PR (1992b) Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm [GenSect] 89: 129–133

    Google Scholar 

  • Gleiter CH, Mühlbauer B, Schulz RM, Nilsson E, Antonin KH, Bieck PR (1994) Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. J Neural Transm [GenSect] 95: 241–245

    Google Scholar 

  • Greenawalt JW (1972) Localization of monamine oxidase in rat liver mitochondria. Adv Biochem Psychopharmacol 5: 207–226

    Google Scholar 

  • Greenblatt M, Grosser GM, Wechsler H (1964) Differential response of hospitalized depressed patients to somatic therapy. Am J Psychiatry 120: 935–943

    Google Scholar 

  • Hoencamp E, Haffmans PMJ, Knetering H (1991) Brofaromine in therapy resistant depression. Biol Psychiatry 29 (11S): 374S

  • Hohagen F, Mayer G, Menche A, Riemann D, Volk S, Meier-Ewert KH, Berger M (1993) Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine — a pilot study. J Sleep Res 2: 250–256

    Google Scholar 

  • Jansen PAF, Haffmans PMJ (1992) Evaluation of brofaromine in depressed elderly patients. International Congress Symposion Series 127: 27–30

    Google Scholar 

  • Johnston JP (1968) Some observations upon a new monoamine oxidase inhibitor in brain tissue. Biochem Pharmacol 17: 1285–1297

    Google Scholar 

  • Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'Souza JD, Lofchy J (1993) Is there a role for selective MAO-inhibitor therapy in bulima nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol 13: 415–422

    Google Scholar 

  • Klein DF, Davis JM (1969) Diagnosis and drug treatment of psychiatric disorders. William and Wilkins, Baltimore

    Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408

    Google Scholar 

  • Kucher K, Fuchs L, Antonin KH, Schmidt E, Sulkova S, Valek A, Bieck PR (1992) Pharmacokinetics of the monoamine oxidase inhibitor brofaromine in young healthy volunteers and inpatients with chronic renal failure. Naunyn Schmiedebergs Arch 345 [Suppl]: R10

    Google Scholar 

  • Larsen JK, Holm P, Hoyer E, Mejhede A, Mikkelsen RL, Olesen A, Schaumburg E (1989) Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial. Acta Psychiatr Scand 79: 530–536

    Google Scholar 

  • Lecrubier Y, Guelfi JD (1990) Efficacy of reversible inhibitor of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand 360 [Suppl]: 18–23

    Google Scholar 

  • Lejoyeux H, Adès J, Rouillon F (1994) Serotonin syndrome: Incidence, symptoms and treatment. CNS Drugs 2: 132–143

    Google Scholar 

  • Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine v. imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 41: 669–677

    Google Scholar 

  • Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988) Antidepressant specifity in atypical depression. Arch Gen Psychiatry 45: 129–137

    Google Scholar 

  • Marek GJ, Seiden LS (1988) Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology 96: 153–160

    Google Scholar 

  • McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FR, Klien DF (1993) A double-blind cross-over trial of imipramine and phenelzine for outpatients with treatment refractory depression. Am J Psychiatry 150: 118–123

    Google Scholar 

  • Möller HJ, Wendt G (1989) Brofaromine — a selective, reversible, and short acting MAO-A inhibitor. Psychiatr Praxis 16: 32–36

    Google Scholar 

  • Möller HJ, Volz HP (1992) Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year. J Affect Disord 26: 163–172

    Google Scholar 

  • Möller HJ, Volz HP (1993) Brofaromine in elderly major depressed patients — a comparative trial versus imipramine. Eur Neuropsychopharmacol 3: 501–510

    Google Scholar 

  • Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Hoffmans J (1988) Treatment strategies in depression. II. MAO inhibitors in depression resistent to cyclic antidepressants. Acta Psychiatr Scand 78: 676–683

    Google Scholar 

  • Nolen WA, Haffmans PMJ, Bouvy PF, Daivenvoorden HJ (1993) Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 28: 189–197

    Google Scholar 

  • Ortmann R, Schaub M, Felner A, Lauber J, Christen P, Waldmeier PC (1984) Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84: 22–27

    Google Scholar 

  • Paykel ES (1971) Classification of depressed patients: a cluster analysis derived grouping. Br J Psychiatry 118: 275–288

    Google Scholar 

  • Paykel ES, White JL (1989) A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 155 [Suppl 6]: 9–17

    Google Scholar 

  • Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klien DF, Rabkin JG, Markowitz JS, Wager SG (1988) Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responder. Am J Psychiatriy 145: 306–311

    Google Scholar 

  • Quitkin FM, McGrath PJ, Stewart JW, Harrsion W, Wagner SG, Rabkin JG, Tricamo E, Markowitz J, Klein DF (1989) Phenelzine and imipramine in mood reactive depressives. Arch Gen Psychiatry 46: 787–793

    Google Scholar 

  • Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wagner SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 47: 935–941

    Google Scholar 

  • Quitkin FM, Harrison W, Stewart JW, NcGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wagner SG, Nunes E, Klein DF (1991) Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Arch Gen Psychiatry 48: 319–323

    Google Scholar 

  • Rabkin JG, Quitkin FM, Patrick G, Harrison W, Tricamo E (1985) Adverse reactions to monoamine oxidase inhibitors, part II. Treatment correlates and clinical management. J Clin Psychopharmacol 5: 2–9

    Google Scholar 

  • Raskin A, Schulterbrandt JG, Reatig N, Crook TH, Odle D (1974) Depression subtypes and response to phenelzine, diazepam and a placebo. Arch Gen Psychiatry 30: 66–75

    Google Scholar 

  • Reimann IW, Gleiter CH, Boden C, Joberrt M, Turri M, Antonin KH, Bieck PR (1991) Human pharmaco-EEG of the reversible and selective MAO-A inhibitor brofaromine — comparsion of different modes of data handlung and statistical evaluation. Eur Neuropsychopharmacol 1: 476

    Google Scholar 

  • Roose SP, Glassman AH, Walsh BT, Woodring S (1986) Tricyclic non-responders: phenomenology and treatment. Am J Psychiatry 143: 345–448

    Google Scholar 

  • Sargant W, Dally R (1962) Treatment of anxiety states by anti-depressants. Br Med J 1: 5–9

    Google Scholar 

  • Schatzberg AF, Cole JO, Cohen BM, Altesman RI, Sniffin CM (1983) Survey of depressed patients who failed to respond to treatment. In: Davis JM, Maas JW (eds) Affective disorders. American Psychiatric Press, Washington DC

    Google Scholar 

  • Schiwy W, Heath WR, Delini-Stula A (1989) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine: results of dose-finding trials in depressed patients. J Neural Transm [Suppl 28]: 33–44

    Google Scholar 

  • Schnaitmann C, Erwin VG, Greenawalt JN (1967) The submitochondrial localization of monoamine oxidase. Cell Biol 32: 719–735

    Google Scholar 

  • Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O (1987) Results of an open clinical trial of brofaromine (CGP11 305 A), a competitive, selective, and short acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 29: 262–269

    Google Scholar 

  • Steiger A, Bardeleben U von, Guldner J, Lauer C, Rothe B, Holsboer F (1993) The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry 17: 125–137

    Google Scholar 

  • Strolin Benedetti M, Dostert P (1987) Overview of the present state of MAO inhibiors. J Neural Transm 23 [Suppl]: 103–119

    Google Scholar 

  • Suzuki O, Katsumata Y, Masukazu Q (1982) Substrate specifity of type A and B monoamine oxidase. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase: basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 74–86

    Google Scholar 

  • Thase ME, Mallinger AG, McKnight D, Himmelhoch JM (1992) Treatment of imipramine-resistant recurrent depression. IV. A double-blind crossover study for anergic bipolar depression. Am J Psychiatry 149: 195–198

    Google Scholar 

  • van Vliet IM, Westenberg HGM, den Boer JA (1991) The efficacy of a reversible MAO inhibitor, brofaromine, in panic disorder. Biol Psychiatry 29 (11S): 266S-267S

    Google Scholar 

  • van Vliet IM, den Boer JA, Westenberg HGM (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2: 21–29

    Google Scholar 

  • Volz HP, Faltus F, Magyar I, Möller HJ (1994a) Brofaromine in treatment resistant major depressed patients — a comparative trial versus tranylcypromine. J Affect Disord 30: 209–217

    Google Scholar 

  • Volz HP, Heimann H, Bellaire J, Laux G, Möller HJ (1994b) Brofaromine in nonendogenous major depressed inpatients. Results of a preliminary dose-finding trial versus tranylcypromine. Pharmacopsychiatry 4: 152–158

    Google Scholar 

  • Volz HP, Möller HJ (1995) Brofaromine in major depressed in-patients: a controlled clinical trial versus imipramine. Eur Neuropsychopharmacol (submitted)

  • Waldmeier F, Czendlik C, Faigle JW, Moppert J (1988) Disposition and biotransformation of the MAO-A inhibitor trial drug brofaromine in healthy male volunteers. Xlth European Drug Metabolism Workshop, Konstanz, Germany (Abstract No 2.80)

  • Waldmeier PC, Felner AE, Maitre L (1981) Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — the state of the art. Wiley, Chichester, pp 87–102

    Google Scholar 

  • Waldmeier PC, Baumann PA (1983) Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO-A, on biogenic amine levels and metabolism in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 324: 20–26

    Google Scholar 

  • Waldmieier PC, Felner AE, Tipton KF (1983a) The monoamine oxidase inhibiting properties of CGP 11 305A. Eur J Pharmacol 94: 73–83

    Google Scholar 

  • Waldmeier PC, Feldtrauer JJ, Stöcklin K, Paul E (1983a) Reversibility of the interaction of CGP 11305 A with MAO-A in vivo. Eur J Pharmacol 94: 101–108

    Google Scholar 

  • Waldmeier PC, Baumann PA, Delini-Stula A, Beranasconi R, Sigg K, Buech O, Felner AE (1983c) Characterisation of a new, short acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsychiatry 19: 31–52

    Google Scholar 

  • Waldmeier PC (1984) Effects of chronic antidepressant treatment on pre- and postsynaptic dopaminergic mechanisms. A short review of the literature and some complementary experiments. Pol J Pharmacol Pharm 36: 197–212

    Google Scholar 

  • Waldmeier PC, Stöcklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197–204

    Google Scholar 

  • Waldmeier PC, Stöcklin K (1990) Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide. Eur J Pharmacol 180: 297–304

    Google Scholar 

  • Waldmeier PC, Stöcklin K (1992) Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine. Eur J Pharmacol 216: 243–247

    Google Scholar 

  • Waldmeier PC (1993) Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Prog Neuropsychopharmacol Biol Psychiatry 17: 183–198

    Google Scholar 

  • Waldmeier PC, Glatt A, Jaekel J, Bittiger H (1993a) Brofaromine: a monoamine oxidase- A and serotonin uptake inhibitor. Clin Neuropharmacol 16 [Suppl 2]: S19-S24

    Google Scholar 

  • Waldmeier PC, Graf T, Germer M, Feldtrauer JJ, Howald H (1993b) Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. Biol Psychiatry 33: 373–379

    Google Scholar 

  • West ED, Daily LJ (1959) Effects of iproniazid in depressive syndromes. Br Med J 1: 1491–1494

    Google Scholar 

  • Wollmann H, Nilsson E, Antonin KH, Bieck PR (1985) Tryptamine kinetics in human volunteers. In: Boulton AA, Maitre L, Bieck PR, Riederer P (eds) Neurobiology of the trace amines. Humana Press, Clifton NJ, pp 361–378

    Google Scholar 

  • Yang HY, Neff NH (1973) Beta-phenylethylamine: a specific substrate of type B monoamine oxidase in brain. J Pharmacol Exp Ther 187: 365–371

    Google Scholar 

  • Zeeh J, Bermann W, Fuchs L, Antonin KH, Platt D, Bieck RP (1993) Pharmacokinetics of brofaromine in young healthy volunteers and frail elderly patients — can quantitative liver function test predict individual kinetic behaviour? XVth World Congress of Gerontology, July 4–7, Budapest

  • Zisook S (1985) A clinical overview of monoamine oxidase inhibitors. Psychosomatics 26: 240–246

    Google Scholar 

Download references

Author information

Author notes

  1. H. -P. Volz

    Present address: Psychiatrische Klinik und Poliklinik, Friedrich-Schiller-Universität Jena, Jena

Authors and Affiliations

  1. Abteilung Klinische Pharmakologie, Zentrum für Pharmakologie und Toxikologie der Georg-August-Universität, Göttingen, Federal Republic of Germany

    C. H. Gleiter

  2. Research Department CNS, Basel, Switzerland

    P. C. Waldmeier

  3. International Clinical Research CNS, Ciba-Geigy Ltd., Basel, Switzerland

    M. Struck

  4. Psychiatrische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München, Federal Republic of Germany

    H. -J. Möller

Authors
  1. H. -P. Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. H. Gleiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. C. Waldmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Struck
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. -J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volz, H.P., Gleiter, C.H., Waldmeier, P.C. et al. Brofaromine — a review of its pharmacological properties and therapeutic use. J. Neural Transmission 103, 217–245 (1996). https://doi.org/10.1007/BF01292628

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01292628

Keywords

Search

Navigation